COPENHAGEN, Denmark, May 4, 2009 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on May 29, 2009 to review the Arzerra(TM) (ofatumumab) Biologics License Application (BLA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.
